Current Hematologic Malignancy Reports

Papers
(The H4-Index of Current Hematologic Malignancy Reports is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Circulating Tumor DNA in Lymphoma73
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia38
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies36
Future Directions in Chronic Phase CML Treatment35
MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications26
IDH Inhibitors in AML—Promise and Pitfalls22
Monoclonal Gammopathy-Associated Neuropathy20
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations19
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia18
JAK Inhibitors for Myelofibrosis: Strengths and Limitations16
Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management16
Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?16
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms15
0.033430099487305